Men are more prone to take risks for personal financial gain than women, and women are more likely than men to take risks to protect themselves from financial loss. Pexels

When motorcycle daredevil Evel Knievel leapt over cars, vans and fountains, it was little surprise that the person pulling those stunts was a man. That's not to say women never partake in high-risk behavior (Danica Patrick, anyone?). But decades of research confirm that men really are more inclined to take risks.

Snake River Canyon and the Indy 500 aside, economic life offers plenty of risks as well. When these risks involve investing, men under certain circumstances are more likely than women to take dangerous leaps, but why?

Rice Businesses professor Vikas Mittal joined Xin He of the University of Florida and J. Jeffrey Inman of the University of Pittsburgh in three studies to examine why men and women engage in risky business. Specifically, the team wanted to test whether each gender's risk-taking was moderated by a trait called issue capability: a decision-makers' belief that he or she can solve an issue.

The team grounded their work in agency-communion theory. This posits that men are more driven by goals that further self-interest ("agentic" goals) and women are more driven by goals that further coexistence ("communion" goals).

Based on this theory, the researchers hypothesized that men making investment decisions would take greater risks as their issue capability rose. This would occur because men, who are more focused on maximizing gains, would become more risk-seeking as their self-capability perceptions increased.

Conversely, the researchers theorized, women who faced similar investment decisions would focus on avoiding loss — even when their issue capability rose. This fundamental difference in investing perspective — men trying to maximize any gain versus women trying to minimize any loss – would be at the heart of a diametrically opposite stance on financial risk-taking.

All three studies proved the theory to be correct.

In the first study, the researchers asked men and women to wager money on Daily Double questions in "Jeopardy!" The male contestants with higher issue capability (i.e. demonstrated knowledge of the category) took the biggest risks. The women contestants showed equal levels of betting behavior regardless of whether they had high issue capability or not.

In the second study, the researchers dove into the psychology underlying gender and issue capability. First, the researchers primed male and female participants to believe they had either good or bad track records with risky investment decisions. Then they asked both groups to imagine they could invest $20,000 at varying levels of risk.

When it came to investing for gains, the researchers found, the women's beliefs about their issue capability made no real difference in their financial choices. Even after they had been primed to think they were highly capable investors, the women participants were less prone than the men to focus on the upside potential

And the men? Those who believed they were "capable" made the riskiest investment decisions. They also reported the highest number of thoughts about the positive potential of the various investment scenarios. Statistical analysis proved that these gain-maximization thoughts egged them on in their risk-taking.

On the other hand, those male participants who weren't primed to feel capable showed risk-taking patterns identical to that of the female participants. The results, in other words, suggest that the key difference between men and women's risk-taking is not innate — but stems from their self-conviction in investment competence.

The third study examined these processes in yet another way, by giving female and male participants the chance to maximize gains through making investments in stocks, or to minimize losses through buying insurance. Once again, the men primed to see themselves as ace investors made the riskiest investments. The women who felt themselves especially capable kept their risk-taking steady.

The women's behavior only changed when they thought they were subpar investors. When both women and men were told they were stock market duds, the women were more likely than the men to buy insurance — in other words, to take traditional measures to defend against loss.

Risk-taking choices, in other words, can no longer be written off as just boys being boys or girls being girls. More accurately, boys will be boys when a male investor thinks he is especially capable and that taking a risk will benefit him personally. That's not always a good thing. A female investor, who will typically focus on minimizing potential loss, can contribute a lot to investing decisions. Taking a big risk, as many an investor knows, isn't always the best move.

Mittal's findings inspire a list of possibilities for future research. What will happen to these behaviors as more women assume leadership jobs and more men get to show their skill as caregivers? Should senior management teams have both male and female representation to balance out the upsides and downsides of investment decisions? What about at home: would household decisions change for the better if both the man and the woman contributed their perspective?

------

This story originally ran on Rice Business Wisdom.

Vikas Mittal is the J. Hugh Liedtke Professor of Marketing at Jones Graduate School of Business at Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”